An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Fevipiprant (Primary)
- Indications Liver dysfunction
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 02 Mar 2018 Planned End Date changed from 30 Jun 2018 to 25 Jun 2018.
- 02 Mar 2018 Planned primary completion date changed from 30 Jun 2018 to 25 Jun 2018.
- 02 Mar 2018 Status changed from not yet recruiting to recruiting.